{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011496","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.913854+00:00","generated_at":"2026-06-25T02:55:25.981973+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tenaya Therapeutics reports stockholder votes from 2022 annual meeting","bullets":["Four Class I directors elected: David Goeddel (34,063,079 for), Karah Parschauer (34,833,578), Jeffrey Walsh (34,112,810), R. Sanders Williams (34,135,556); 829,857 broker non-votes each.","Ratification of Deloitte & Touche as independent auditor for FY2022: 35,984,423 for, 148 against, 244 abstain; no broker non-votes.","All director nominees will serve until the 2025 annual meeting or until successors are elected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011496","json":"https://secwatch.observer/filing/0000950170-22-011496.json","markdown":"https://secwatch.observer/filing/0000950170-22-011496.md","text":"https://secwatch.observer/filing/0000950170-22-011496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022011496/0000950170-22-011496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022011496/tnya-20220609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:55:25.981973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}